TMCP2 is a vaccine candidate to treat Gonorrhea. It is a complex peptide that is both scalable and economically produced to a high degree of purity.
The candidate elicits bactericidal (killing) antibodies and is efficacious in a preclinical experimental infection model.”
The vaccine formulation also includes an adjuvant to increase the immune response.
TMCP2 is indicated to prevent gonorrhea, a sexually transmitted infection that affects men and women. Untreated, gonorrhea can cause infertility in women.
The vaccine was tested over a range of doses and administration intervals in an animal model. The vaccine elicited a durable and robust immune response, one that significantly reduced both the duration of infection and the level of gonococcal colonization.